Related references
Note: Only part of the references are listed.The prognostic and predictive value of serum CA19.9 in pancreatic cancer
J. L. Humphris et al.
ANNALS OF ONCOLOGY (2012)
Prognostic Impact of Postoperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer
Shojiro Hata et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial
Michele Reni et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
Peter J. Hosein et al.
BMC CANCER (2012)
Arterial Resection During Pancreatectomy for Pancreatic Cancer A Systematic Review and Meta-Analysis
Nathan Mollberg et al.
ANNALS OF SURGERY (2011)
Pancreatic Cancer Surgery in the New Millennium Better Prediction of Outcome
Werner Hartwig et al.
ANNALS OF SURGERY (2011)
Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
Philip Q. Bao et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Failure of Normalization of CA19-9 Following Resection for Pancreatic Cancer is Tantamount to Metastatic Disease
Sherif R. Z. Abdel-Misih et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the US Intergroup/RTOG 9704 Phase III Trial
William F. Regine et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Major Molecular Markers in Pancreatic Ductal Adenocarcinoma and Their Roles in Screening, Diagnosis, Prognosis, and Treatment
Puneet Singh et al.
PANCREAS (2011)
Serum CA19-9 Alterations During Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Invasive Ductal Carcinoma of the Pancreas as an Indicator for Therapeutic Selection and Survival
Hidenori Takahashi et al.
ANNALS OF SURGERY (2010)
Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
Matthew H. G. Katz et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer
Naru Kondo et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy
J. Bernhard et al.
BRITISH JOURNAL OF CANCER (2010)
Molecular Predictors of Outcome in a Phase 3 Study of Gemcitabine and Erlotinib Therapy in Patients With Advanced Pancreatic Cancer National Cancer Institute of Canada Clinical Trials Group Study PA 3
Gilda da Cunha Santos et al.
CANCER (2010)
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial
John P. Neoptolemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Multivisceral Resection for Pancreatic Malignancies Risk-Analysis and Long-Term Outcome
Werner Hartwig et al.
ANNALS OF SURGERY (2009)
Resectable Pancreatic Cancer: Who Really Benefits From Resection?
Giuliano Barugola et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
H. S. Wasan et al.
BRITISH JOURNAL OF CANCER (2009)
Carbohydrate Antigen 19-9 Change During Chemotherapy for Advanced Pancreatic Adenocarcinoma
Michele Reni et al.
CANCER (2009)
Very High Serum CA 19-9 Levels: A Contraindication to Pancreaticoduodenectomy?
O. Turrini et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2009)
Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma
Joshua G. Barton et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2009)
Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma
Shishir K. Maithel et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704
Adam C. Berger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
Viviane Hess et al.
LANCET ONCOLOGY (2008)
Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy
C. M. Halloran et al.
BRITISH JOURNAL OF SURGERY (2008)
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
Cristina R. Ferrone et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer
A Karachristos et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2005)
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
NR Maisey et al.
BRITISH JOURNAL OF CANCER (2005)
Utility of tumor markers in determining resectability of pancreatic cancer
MG Schlieman et al.
ARCHIVES OF SURGERY (2003)
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice
DV Mann et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2000)
Share Paper
